EX
EX9.F Exelixis Inc
- Market cap
- EUR 15.4B
- P/E
- 21.8x
- P/B
- 9.45x
- ROE
- 46.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EX9.F undervalued?
Graham numberThe Graham number of Exelixis Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Exelixis Inc fundamental analysis
No fundamental analysis for Exelixis Inc yet.
Exelixis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibito…
Full company profileExelixis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Exelixis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 191M | 452M | 854M | 968M | 988M | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B | 2.53B |
| Gross Profit | 185M | 437M | 827M | 935M | 951M | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B | 2.44B |
| Operating Income | -27.2M | 166M | 439M | 369M | 110M | 287M | 201M | 171M | 690M | 893M | 1.02B |
| EBITDA | - | 168M | 460M | 406M | 119M | - | 222M | 197M | 719M | 922M | 1.05B |
| Net Income | -70.2M | 154M | 690M | 321M | 112M | 231M | 182M | 208M | 521M | 783M | 854M |
| EPS | - | 0.52 | 2.30 | 1.05 | 0.36 | 0.72 | 0.56 | 0.69 | 1.85 | 2.98 | 3.49 |
| Balance Sheet | |||||||||||
| Total Assets | 598M | 655M | 1.42B | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B | 2.84B | 2.51B |
| Total Liabilities | 508M | 370M | 135M | 200M | 258M | 406M | 583M | 678M | 703M | 683M | 680M |
| Shareholders' Equity | 89.3M | 285M | 1.29B | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B | 1.83B |
| Cash & Short-term Investments | 152M | 183M | 315M | 267M | 319M | 647M | 501M | 263M | 217M | 482M | 305M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 210M | 166M | 416M | 527M | 209M | 401M | 363M | 396M | 700M | 884M | 1.12B |
| Capital Expenditure | 1.70M | 21.1M | 33.3M | 12.8M | 30.3M | 54.2M | 27.7M | 262M | 66.2M | 39.9M | 28.6M |
| Free Cash Flow | - | 144M | 382M | 514M | 179M | 337M | 224M | 134M | 634M | 844M | 1.09B |
| Ratios | |||||||||||
| ROE | -78.6% | 54.1% | 53.6% | 19.0% | 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% | 46.6% |
| ROA | -11.8% | 23.5% | 48.5% | 17.0% | 5.2% | 8.8% | 5.9% | 7.1% | 17.7% | 27.5% | 34.0% |
| Net Profit Margin | -36.7% | 34.1% | 80.8% | 33.2% | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% | 33.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Exelixis Inc dividends
Exelixis Inc has not paid dividends in the last 9 fiscal years.
Who owns Exelixis Inc
- Insiders 1.87%
- Institutions 98.13%
- Public & others 0.00%
- Shares outstanding 244M
- Free float 209M
Exelixis Inc company profile
- Company name
- Exelixis Inc
- Ticker
- EX9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,077
- Fiscal year end
- December
- Address
- 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
- Phone
- 650 837 7000
- Website
- exelixis.com
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Exelixis Inc management
10- Dr. Stelios Papadopoulos Ph.D.Co-Founder & Independent Chair of the Board · born 1948
- Dr. Michael M. Morrissey Ph.D.CEO, President & Director · born 1961
- Mr. Christopher J. SennerExecutive VP & CFO · born 1968
- Dr. Brenda J. Hefti J.D., Ph.D.Senior VP & General Counsel · born 1974
- Dr. Dana T. Aftab Ph.D.Executive Vice President of Research & Development · born 1964
- Mr. Patrick Joseph Haley M.B.A.Executive Vice President of Commercial · born 1976
- Dr. William Berg M.D.Senior Vice President of Medical Affairs
- Dr. Stefan Krauss Ph.D.VP & Head of Business Development
- Mr. Andrew Ross PetersSenior Vice President of Strategy
- Ms. Deborah Burke CPASenior VP of Finance & Controller · born 1956